MAPP and AGN Related Headlines
Go Back- UPDATE: Wedbush Downgrades MAP Pharma (MAPP) to Neutral, Notes Other Potential M&A Targets
- ACADIA Pharmaceuticals (ACAD) Sees Early Action on Partner Deal
- NuPathe (PATH) on the Radar on Sector Deal
- Allergan (AGN) Acquires MAP Pharmaceuticals (MAPP) for $958M
- Canaccord Genuity Reiterates a 'Buy' on MAP Pharmaceuticals (MAPP); Update From Global Growth Conference
